{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+%28Investigator+Selected%29&page=2", "query": { "intervention": "Standard of Care (Investigator Selected)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 101, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+%28Investigator+Selected%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+%28Investigator+Selected%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T18:11:26.337Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07458230", "title": "Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation:", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Next Generation Sequencing (NGS)", "Surgical Site Infection (SSI)", "Fracture Fixation" ], "interventions": [ { "name": "NGS diagnostic findings", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Johns Hopkins Bloomberg School of Public Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 250, "start_date": "2026-11-01", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-09T18:11:26.337Z", "location_count": 18, "location_summary": "Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07458230" }, { "nct_id": "NCT04215991", "title": "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gram-negative Bacterial Infections", "Hospital Acquired Bacterial Pneumonia (HABP)", "Complicated Urinary Tract Infection (cUTI)", "Ventilator Associated Bacterial Pneumonia (VABP)" ], "interventions": [ { "name": "Cefiderocol", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shionogi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "3 Months to 17 Years" }, "enrollment_count": 91, "start_date": "2020-02-19", "completion_date": "2024-09-17", "has_results": false, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-10-09T18:11:26.337Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Fort Worth, Texas", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04215991" }, { "nct_id": "NCT06072612", "title": "Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Metastatic Breast Cancer", "Breast Neoplasm", "Breast Cancer Metastatic", "End Stage Cancer" ], "interventions": [ { "name": "SV-BR-1-GM", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Interferon infiltration of the inoculation site", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "Treatment of Physician's Choice", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "BriaCell Therapeutics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 404, "start_date": "2023-12-05", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-09T18:11:26.337Z", "location_count": 79, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06072612" }, { "nct_id": "NCT03163446", "title": "Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Staphylococcus Aureus Bacteremia", "Staphylococcus Aureus Endocarditis" ], "interventions": [ { "name": "CF-301", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "ContraFect", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2017-05-23", "completion_date": "2019-03-07", "has_results": true, "last_update_posted_date": "2021-10-08", "last_synced_at": "2026-10-09T18:11:26.337Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT03163446" }, { "nct_id": "NCT01156571", "title": "A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerosis", "Percutaneous Coronary Intervention", "Acute Coronary Syndrome" ], "interventions": [ { "name": "cangrelor P2Y12 (platelet) inhibitor", "type": "DRUG" }, { "name": "Clopidogrel - 300 or 600 mg (study arm)", "type": "DRUG" }, { "name": "Clopidogrel 600 mg post cangrelor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Medicines Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11145, "start_date": "2010-09", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2014-02-04", "last_synced_at": "2026-10-09T18:11:26.337Z", "location_count": 1, "location_summary": "Anderson, South Carolina", "locations": [ { "city": "Anderson", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01156571" }, { "nct_id": "NCT07170605", "title": "The Building Resilience Program: Examining Self-Regulation, Behavior, and Resilience in Under-Resourced Preschoolers With ACEs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Preschool Age Children", "Preschool Education", "Adverse Childhood Experience", "Mental Health", "Resilience", "Minority Groups" ], "interventions": [ { "name": "Mental health, positive coping strategies promoting self-regulation and adaptive skills", "type": "BEHAVIORAL" }, { "name": "Standard care/School Readiness Condition", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Cleveland State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "24 Months", "maximum_age": "66 Months", "sex": "ALL", "summary": "24 Months to 66 Months" }, "enrollment_count": 38, "start_date": "2023-10-01", "completion_date": "2024-09-30", "has_results": false, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-10-09T18:11:26.337Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07170605" }, { "nct_id": "NCT05945823", "title": "Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Cancer", "Siewert Type 1 GEJ Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "Futibatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2023-07-13", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-09T18:11:26.337Z", "location_count": 16, "location_summary": "Santa Monica, California • Denver, Colorado • Miami Beach, Florida + 13 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05945823" }, { "nct_id": "NCT04092283", "title": "Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Lung Non-Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed Disodium", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 660, "start_date": "2020-04-29", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-09T18:11:26.337Z", "location_count": 829, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 549 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04092283" }, { "nct_id": "NCT02187302", "title": "CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "CRLX101", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Standard of Care (Investigator Choice)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NewLink Genetics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2014-07", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2020-05-28", "last_synced_at": "2026-10-09T18:11:26.337Z", "location_count": 38, "location_summary": "La Jolla, California • Los Angeles, California • Denver, Colorado + 33 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02187302" }, { "nct_id": "NCT05934448", "title": "Pembro Plus CAR T-cell Therapy in R/R in PMBCL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "Primary Mediastinal Large B Cell Lymphoma", "Primary Mediastinal Large B-Cell Lymphoma Refractory", "Primary Mediastinal Large B-Cell Lymphoma Recurrent", "Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma", "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Lymphodepletion Chemotherapy", "type": "DRUG" }, { "name": "Chimeric Antigen Receptor (CAR) Therapy Infusion", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Jennifer Crombie, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2023-11-15", "completion_date": "2031-06-06", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-09T18:11:26.337Z", "location_count": 2, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05934448" } ] }